Summary
Boston Scientific Corporation (BSX) has announced a significant strategic move with the signing of a definitive merger agreement to acquire Sadra Medical, Inc. This acquisition is set to enhance BSX's presence in the cardiovascular market by adding Sadra's innovative, fully repositionable device for percutaneous aortic valve replacement. This technology addresses a critical need for patients suffering from severe aortic stenosis, offering a potentially less invasive treatment option compared to traditional open-heart surgery.
Key Highlights
- 1Boston Scientific (BSX) to acquire Sadra Medical, Inc.
- 2Acquisition targets a development-stage company with a novel medical device.
- 3Sadra Medical is developing a fully repositionable device for percutaneous aortic valve replacement.
- 4The technology aims to treat patients with severe aortic stenosis.
- 5Transaction is expected to close in late 2010 or early 2011.
- 6This acquisition strengthens BSX's cardiovascular portfolio.